Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early... Background BACE1 is a key protease targeting the amyloid processing pathways in AD. Previously we published on LY2811376, the first small molecule BACE1 inhibitor reported to provide robust CSF Abeta changes in healthy subjects. LY2811376 progressed to clinical trials but was terminated due to non-clinical tox findings. Here we report the preclinical pharmacology of LY2886721, a new BACE1 inhibitor that is in clinical development for early AD. Methods Enzyme assays were conducted with recombinant enzymes using a FRET platform. Cell based assays were conducted with either a HEK293Swe cell line or primary neuronal cultures prepared from PDAPP mice. D ose response and time course studies were conducted in young PDAPP transgenic mice with brain collected at various times after oral gavage and extracts analyzed by ELISA for relevant PD biomarkers including Abeta, C99 and sAPPbeta. Plasma and CSF PK/PD studies were conducted in beagle dogs using a multi-week paradigm which involved establishing vehicle-treated baseline CSF Abeta values for within dog comparison to subsequent CSF samples taken from LY-treated dogs. Results LY2886721 inhibited recombinant hBACE1 with an IC50 of 20.3 nM. In cellular assays, LY2886721 inhibited Abeta with an IC50 of 18.7 nM and 10.7 nM, HEK293Swe and PDAPP http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alzheimer's and Dementia Elsevier

Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease

Loading next page...
 
/lp/elsevier/preclinical-characterization-of-ly2886721-a-bace1-inhibitor-in-OoBN4OW6aq
Publisher
Elsevier
Copyright
Copyright © 2012 Elsevier Ltd
ISSN
1552-5260
D.O.I.
10.1016/j.jalz.2012.05.2125
Publisher site
See Article on Publisher Site

Abstract

Background BACE1 is a key protease targeting the amyloid processing pathways in AD. Previously we published on LY2811376, the first small molecule BACE1 inhibitor reported to provide robust CSF Abeta changes in healthy subjects. LY2811376 progressed to clinical trials but was terminated due to non-clinical tox findings. Here we report the preclinical pharmacology of LY2886721, a new BACE1 inhibitor that is in clinical development for early AD. Methods Enzyme assays were conducted with recombinant enzymes using a FRET platform. Cell based assays were conducted with either a HEK293Swe cell line or primary neuronal cultures prepared from PDAPP mice. D ose response and time course studies were conducted in young PDAPP transgenic mice with brain collected at various times after oral gavage and extracts analyzed by ELISA for relevant PD biomarkers including Abeta, C99 and sAPPbeta. Plasma and CSF PK/PD studies were conducted in beagle dogs using a multi-week paradigm which involved establishing vehicle-treated baseline CSF Abeta values for within dog comparison to subsequent CSF samples taken from LY-treated dogs. Results LY2886721 inhibited recombinant hBACE1 with an IC50 of 20.3 nM. In cellular assays, LY2886721 inhibited Abeta with an IC50 of 18.7 nM and 10.7 nM, HEK293Swe and PDAPP

Journal

Alzheimer's and DementiaElsevier

Published: Jul 1, 2012

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off